tert-butyl glycyl-D-valinate hydrochloride | 857506-75-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl glycyl-D-valinate hydrochloride
• 英文别名: tert-butyl (2R)-2-[(2-aminoacetyl)amino]-3-methylbutanoate;hydrochloride
• CAS: 857506-75-3
• 化学式: C₁₁H₂₂N₂O₃*ClH
• 分子量: 266.768
• InChiKey: KPAXELFPYJREEH-SBSPUUFOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.85
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  81.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl glycyl-D-valinate hydrochloride 在 N-甲基吗啉 、 sodium tetrahydroborate 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.75h， 生成 N-[(4-{(2R,3R)-1-(4-fluorophenyl)-3-[(2-hydroxy-2-phenylethyl)thio]-4-oxoazetidin-2-yl}phenoxy)acetyl]glycyl-D-valine
  参考文献：
  名称：

  [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY
  [FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL

  摘要：

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。

  公开号：

  WO2005061452A1
• 作为产物：
  描述：

  D-缬氨酸叔丁基盐酸盐 在 95% Pd/C N-甲基吗啉 、 氢气 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 74.0h， 生成 tert-butyl glycyl-D-valinate hydrochloride
  参考文献：
  名称：

  [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY
  [FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL

  摘要：

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。

  公开号：

  WO2005061452A1

文献信息

• [EN] DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE PRESENTANT UNE ACTIVITE D'INHIBITION D'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061451A1

  公开（公告）日：2005-07-07

  Compounds of formula (XV): [Chemical formula should be inserted here. Please see paper copy] (XV) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  公式（XV）的化合物：[应在此处插入化学公式。请参见纸质副本]（XV）（其中变量组如内部定义）药物可接受的盐、溶剂化物、这些盐的溶剂化物和前药及其用作治疗高脂血症的胆固醇吸收抑制剂。还描述了它们的制造过程和含有它们的药物组合物。
• Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
  申请人：Alenfalk Susanne

  公开号：US20080064676A1

  公开（公告）日：2008-03-13

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式(I)的化合物（其中变量基团如定义所示），其药学上可接受的盐、此类盐的溶剂化合物、其前药以及其作为治疗高脂血症的胆固醇吸收抑制剂的用途。本文还描述了其制造工艺和含有它们的制药组合物。
• Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity
  申请人：Alenfalk Susanne

  公开号：US20070142304A1

  公开（公告）日：2007-06-21

  Compounds of formula (XV): [Chemical formula should be inserted here. Please see paper copy] (XV) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  化合物的化学式（XV）：[应在此处插入化学式。请参阅纸质副本]（其中变量基团的定义如下），所述化合物的药学上可接受的盐，溶剂化合物，该类盐的溶剂化合物和其前药的用途作为胆固醇吸收抑制剂，用于治疗高脂血症。还描述了其制造过程和含有它们的制药组合物。
• Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
  申请人：AstraZeneca AB

  公开号：US07871998B2

  公开（公告）日：2011-01-18

  Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式（I）的化合物：（其中变量基团的定义如下）药学上可接受的盐，其溶剂化物，这些盐的溶剂化物及其前药，并将其用作胆固醇吸收抑制剂，用于治疗高脂血症。还描述了它们的制造过程和含有它们的制药组合物。
• Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
  申请人：Dahlstrom Mikael

  公开号：US20100168075A1

  公开（公告）日：2010-07-01

  The application relates to novel 2-azetidinone derivatives of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds are cholesterol absorption inhibitors and are useful in the treatment of hyperlipidaemic conditions, including atherosclerosis, Alzheimers' disease and cholesterol associated tumours. The application also relates to pharmaceutical formulations comprising such compounds and to processes for their preparation.

  该申请涉及公式（I）的新型2-氮杂环己酮衍生物及其药学上可接受的盐、溶剂和前药。这些化合物是胆固醇吸收抑制剂，可用于治疗高脂血症状况，包括动脉硬化、阿尔茨海默病和胆固醇相关肿瘤。该申请还涉及包含这些化合物的制药配方以及它们的制备过程。